ASND

Ascendis Pharma AS

120.64 USD
-0.48 (-0.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ascendis Pharma AS stock is down -13.93% since 30 days ago. The next earnings date is Sep 3, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 9 PUTs, 1 CALL. 60% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Apr 15:46 20 Dec, 2024 105.00 PUT 21 2
13 May 14:26 17 May, 2024 95.00 PUT 100 103
13 May 14:40 17 May, 2024 100.00 PUT 88 326
13 May 16:52 17 May, 2024 130.00 PUT 25 364
13 May 19:36 17 May, 2024 130.00 PUT 49 364
13 May 19:36 17 May, 2024 130.00 CALL 40 26
14 May 18:34 19 Jul, 2024 105.00 PUT 100 1
14 May 18:36 18 Oct, 2024 90.00 PUT 30 30
15 May 15:21 21 Jun, 2024 125.00 PUT 90 35
17 May 18:15 18 Oct, 2024 95.00 PUT 35 10

About Ascendis Pharma AS

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

  • Morgan Stanley
    Thu May 16, 12:00
    hold
    confirm
  • Wells Fargo
    Fri May 3, 14:01
    buy
    confirm
  • JP Morgan
    Fri May 3, 11:17
    buy
    confirm
  • Cantor Fitzgerald
    Fri May 3, 10:58
    buy
    confirm
  • Morgan Stanley
    Mon Apr 22, 13:15
    hold
    confirm